📊 NRXS Key Takeaways
Is Neuraxis, INC (NRXS) a Good Investment?
Neuraxis exhibits severe fundamental distress with substantial operating losses despite high gross margins, indicating critical execution and operational efficiency issues. The company is burning cash rapidly with negative free cash flow of -6.5M against only 3.6M in annual revenue, while relying on depleting cash reserves to sustain operations.
Neuraxis shows elite gross margins but no revenue growth, while operating and net losses remain extreme, driving substantial cash burn. Liquidity is adequate short term and leverage is low, yet free cash flow of -$6.46M against $4.97M cash suggests a short runway and likely financing/dilution. Until revenue accelerates and operating efficiency improves materially, fundamentals remain unattractive.
Why Buy Neuraxis, INC Stock? NRXS Key Strengths
- Strong gross margin of 84.2% indicates viable product economics
- Solid liquidity position with 2.05x current ratio and 5.0M cash reserves
- Low leverage with 0.05x debt-to-equity ratio provides financial flexibility
- High 84% gross margin indicating strong unit economics
- Low leverage (0.05x D/E) reducing insolvency risk
- Near-term liquidity support (current ratio ~2x, ~$5M cash)
NRXS Stock Risks: Neuraxis, INC Investment Risks
- Massive operating losses of -7.8M with -219.4% operating margin indicate unsustainable business model
- Negative free cash flow of -6.5M annually will deplete 5.0M cash reserves within approximately 9 months at current burn rate
- Revenue stagnation (0.0% YoY growth) combined with rising operating expenses demonstrates inability to scale profitably
- Highly negative returns on equity (-229.5%) and assets (-121.8%) show value destruction
- Operating cash flow of -6.4M indicates core business operations are not self-sustaining
- Severely negative operating and net margins with large losses
- Flat revenue (0% YoY) undermines growth quality
- High cash burn and limited runway, likely capital raise/dilution
Key Metrics to Watch
- Operating cash flow trajectory and path to cash flow breakeven
- Revenue growth acceleration and operating expense control
- Cash runway and timeline to profitability or need for capital raise
- Gross margin sustainability as company scales
- Customer acquisition and retention metrics
- Quarterly revenue growth
- Operating cash burn and runway
Neuraxis, INC (NRXS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.05x current ratio provides a solid financial cushion.
NRXS Profit Margin, ROE & Profitability Analysis
NRXS vs Healthcare Sector: How Neuraxis, INC Compares
How Neuraxis, INC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Neuraxis, INC Stock Overvalued? NRXS Valuation Analysis 2026
Based on fundamental analysis, Neuraxis, INC has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Neuraxis, INC Balance Sheet: NRXS Debt, Cash & Liquidity
NRXS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Neuraxis, INC's revenue has grown significantly by 33% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.22 indicates the company is currently unprofitable.
NRXS Revenue Growth, EPS Growth & YoY Performance
NRXS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $666.6K | -$1.7M | $-0.24 |
| Q2 2025 | $611.5K | -$1.7M | $-0.22 |
| Q1 2025 | $646.6K | -$2.1M | $-0.32 |
| Q3 2024 | $477.5K | -$1.8M | $-0.25 |
| Q2 2024 | $611.5K | -$2.1M | $-0.42 |
| Q1 2024 | $646.6K | -$2.1M | $-0.32 |
| Q3 2023 | $477.5K | -$1.2M | $-1.14 |
| Q2 2023 | $646.0K | -$1.2M | $-0.87 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Neuraxis, INC Dividends, Buybacks & Capital Allocation
NRXS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Neuraxis, INC (CIK: 0001933567)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NRXS
What is the AI rating for NRXS?
Neuraxis, INC (NRXS) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 85% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NRXS's key strengths?
Claude: Strong gross margin of 84.2% indicates viable product economics. Solid liquidity position with 2.05x current ratio and 5.0M cash reserves. ChatGPT: High 84% gross margin indicating strong unit economics. Low leverage (0.05x D/E) reducing insolvency risk.
What are the risks of investing in NRXS?
Claude: Massive operating losses of -7.8M with -219.4% operating margin indicate unsustainable business model. Negative free cash flow of -6.5M annually will deplete 5.0M cash reserves within approximately 9 months at current burn rate. ChatGPT: Severely negative operating and net margins with large losses. Flat revenue (0% YoY) undermines growth quality.
What is NRXS's revenue and growth?
Neuraxis, INC reported revenue of $3.6M.
Does NRXS pay dividends?
Neuraxis, INC does not currently pay dividends.
Where can I find NRXS SEC filings?
Official SEC filings for Neuraxis, INC (CIK: 0001933567) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NRXS's EPS?
Neuraxis, INC has a diluted EPS of $-0.95.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NRXS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Neuraxis, INC has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NRXS stock overvalued or undervalued?
Valuation metrics for NRXS: ROE of -229.5% (sector avg: 15%), net margin of -218.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NRXS stock in 2026?
Our dual AI analysis gives Neuraxis, INC a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NRXS's free cash flow?
Neuraxis, INC's operating cash flow is $-6.4M, with capital expenditures of $31.2K. FCF margin is -181.1%.
How does NRXS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -218.5% (avg: 12%), ROE -229.5% (avg: 15%), current ratio 2.05 (avg: 2).